China Resources Shuanghe: Wholly-owned subsidiary Compound Sodium Acetate Rinji Injection was approved for listing.

China Resources Shuanghe announced that its wholly-owned subsidiary, Jingxi Shuanghe, has received the "Drug Registration Certificate" for the compound sodium acetate Ringer's injection issued by the National Medical Products Administration, which is considered to have passed consistency evaluation. This drug is used to supplement extracellular fluid and correct metabolic acidosis. Jingxi Shuanghe started research and development in October 2022 and was approved for listing on January 20, 2026. The company has accumulated research and development investment of 3.8353 million yuan for this drug. In 2024, the total sales of related drugs in China amounted to 1.149 billion yuan, with the top three companies being Jiangsu Zhongda Fanghai, Nanjing Zhongda Tianqing, and Sichuan Kelun Pharmaceutical. Approval will enrich the product line, but sales are uncertain.